Contributions
Abstract: EP469
Type: E-Poster Presentation
Session title: Acute myeloid leukemia - Clinical
Background
Although AML with CEBPAdm indicates a favorable outcome, both our study and data from other studies showed that approximate half of the patients finally relapsed consolidated with chemotherapy alone. Therefore, the heterogeneity of acute myeloid leukemia (AML) with CEBPAdm attracts much attention in recent years.
Aims
The aim of this study was to evaluate the influence of CSF3R mutations and chemosensitivity indexes on prognoses of AML patients with CEBPAdm.
Methods
Sixty-six AML patients with complete genetic mutations and sequential minimal residual disease (MRD) information were retrospectively analyzed in this study.
Results
In AML patients with CSF3R mutations, 56.25% (9/16) of the patients achieving negative MRD after two courses of chemotherapy, which was significantly lower than those without mutation (82.00%, 41/50, P = 0.049). Both CSF3R mutations and MRD status after the second course of chemotherapy associated with long-term outcomes of patients. CSF3R mutated patients showed inferior relapse-free survival (RFS) (5-year RFS: 15.19% vs. 38.7%, P = 0.006) and overall survival (OS) (5-year OS: 8.2% vs. 60.6%, P = 0.038) compared with those with wide-type CSF3R. Negative MRD after the second course of chemotherapy was also an unfavorable indictor for both RFS (5-year RFS: 0.00% vs. 45.5%, P = 0.004) and OS (5-year OS: 0.00% vs. 65.4%, P = 0.050). Finally, a new prognostic model was proposed for AML with CEBPAdm in this study.
Conclusion
Both CSF3R mutations and positive MRD after the second course of chemotherapy were associated with poor outcomes for AML patients with CEBPAdm. An integrity model based on CSF3R mutations and MRD status may be beneficial for evaluating the prognoses of these patients.
Keyword(s):
Abstract: EP469
Type: E-Poster Presentation
Session title: Acute myeloid leukemia - Clinical
Background
Although AML with CEBPAdm indicates a favorable outcome, both our study and data from other studies showed that approximate half of the patients finally relapsed consolidated with chemotherapy alone. Therefore, the heterogeneity of acute myeloid leukemia (AML) with CEBPAdm attracts much attention in recent years.
Aims
The aim of this study was to evaluate the influence of CSF3R mutations and chemosensitivity indexes on prognoses of AML patients with CEBPAdm.
Methods
Sixty-six AML patients with complete genetic mutations and sequential minimal residual disease (MRD) information were retrospectively analyzed in this study.
Results
In AML patients with CSF3R mutations, 56.25% (9/16) of the patients achieving negative MRD after two courses of chemotherapy, which was significantly lower than those without mutation (82.00%, 41/50, P = 0.049). Both CSF3R mutations and MRD status after the second course of chemotherapy associated with long-term outcomes of patients. CSF3R mutated patients showed inferior relapse-free survival (RFS) (5-year RFS: 15.19% vs. 38.7%, P = 0.006) and overall survival (OS) (5-year OS: 8.2% vs. 60.6%, P = 0.038) compared with those with wide-type CSF3R. Negative MRD after the second course of chemotherapy was also an unfavorable indictor for both RFS (5-year RFS: 0.00% vs. 45.5%, P = 0.004) and OS (5-year OS: 0.00% vs. 65.4%, P = 0.050). Finally, a new prognostic model was proposed for AML with CEBPAdm in this study.
Conclusion
Both CSF3R mutations and positive MRD after the second course of chemotherapy were associated with poor outcomes for AML patients with CEBPAdm. An integrity model based on CSF3R mutations and MRD status may be beneficial for evaluating the prognoses of these patients.
Keyword(s):